Skip to main content

Strong and thriving communities

We believe community engagement is a foundational aspect of responsible corporate citizenship.

 

As a biopharmaceutical company, our opportunity to give back to society starts with the innovative medicines we discover, develop and deliver. Making our medicines accessible to patients who need them is critical to our mission as scientific stewards. However, for people without reliable access to health and wellness services, that’s not enough. That’s why we support community-based programs that enhance access to health care more broadly and build long-term community strength.

Health access for the underserved

We give our medicines, expertise and funding to help meet the needs of those who are underserved.

  • Donating medicines: Through our medicine donation programs, we provide medicines to underserved populations who typically have no other means of accessing them. We have seven ongoing medicine donation partnerships with organizations providing care in low- and middle-income countries, donating medicines for use in over 100 countries since 2013. 
  • Country-specific considerations: We strive to maximize patient access by considering local economic development, disease burden and health system needs.

Strengthening community health systems

Addressing the health needs of those who are underserved requires a community-level and on-the-ground approach. AbbVie and the AbbVie Foundation strengthen community health systems through programming and financial support. We focus on areas where our experience and expertise align with significant opportunity to improve public health. The AbbVie Foundation supports organizations and initiatives that further sustainable health care systems in particularly vulnerable communities, including Partners in Health, Texas Children’s Hospital’s Baylor International Pediatric AIDS Initiative (BIPAI), MAP International, University of Chicago Medicine’s Urban Health Initiative and Direct Relief’s Fund for Health Equity. Foundation-supported programs leverage community health workers to encourage prevention, promote early detection, improve disease surveillance and mapping, increase linkage to care and to ultimately reduce health disparities.

  • With support from the AbbVie Foundation, the University of Chicago’s Urban Health Initiative is empowering Chicago's South Side community—made up of 77% Black residents— to advance health equity by enabling local teams of community health workers to promote access to care and resources proven to measurably reduce health disparities.
  • The Foundation’s investment in Direct Relief’s Fund for Health Equity will improve health care services at community health centers, free and charitable clinics and federally qualified health centers across the United States.
  • Our partnership with BIPAI provides a holistic approach to HIV care and treatment, including prevention, comprehensive medical care and psychosocial support in Romania and Malawi.
  • We support MAP International’s multi-faceted, community-based approach to Chagas disease prevention and management in Bolivia, which includes training community health workers, health education, diagnosis and treatment support, and targets vector control.
  • As new medicines become available in medically under-resourced countries, it’s critical that local health systems have the capabilities to support patient safety. We give funding and safety science expertise to initiatives working to strengthen pharmacovigilance systems in Asia, Africa and Latin America.
  • The WHO has set a target to eliminate hepatitis C virus infection by 2030. We are joining the global hepatitis community in supporting a targeted elimination strategy in specific cities, regions or patient groups. In 2018, we launched over 20 projects in 17 countries.

Combating neglected tropical diseases

Neglected tropical diseases (NTDs) and widespread diseases such as malaria and tuberculosis impact close to two billion people globally. These diseases, which disproportionately affect people in low- and middle-income countries, are detrimental to both public health and the economic well-being of communities.

We recognize that combating NTDs requires input and commitment from a wide range of dedicated partners— and that real impact comes from collaboration. AbbVie was one of the original signatories to the London Declaration on Neglected Tropical Diseases in 2012. This collaborative global partnership among pharmaceutical companies, donors, endemic countries and nonprofit organizations aims to eliminate or control 10 NTDs.

Hundreds of AbbVie scientists donate thousands of pro bono hours to help find solutions for these persistent global public health challenges. AbbVie’s Executive Council on Neglected Diseases coordinates our innovative technologies, diverse compounds for screening and scientific expertise, including:

  • Working alongside our partner DNDi to conduct clinical trials that can lead to new treatments for NTDs, such as river blindness.
  • Offering specialized skills and technical support to our partners in the areas of drug discovery and preclinical development.
  • Actively collaborating on partners’ drug discovery and development projects, from synthesizing new compounds and helping design the processes for making partners’ development compounds to conducting preclinical and early clinical testing.
  • Sharing AbbVie’s library of chemical compounds with partners such as DNDi, Tuberculosis Drug Accelerator (TBDA) and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be screened for potential activity against target diseases in the early R&D process.
  • Creating an opportunity for 6-8 chemistry students to participate in a 10-week summer internship program working on NTD related research.

Economic opportunity & supplier diversity

We create business opportunity for thousands of suppliers in more than 131 countries and all U.S. states, the District of Columbia and Puerto Rico. Since 2016, we have conducted more than 130 detailed assessments of labor, health and safety in North America.

Our Supplier Diversity program aligns with our EED&I strategy and is designed to integrate small and diverse businesses into our supply chain. In 2020, we purchased goods and services valued at more than $14.8 billion from 48,000 suppliers around the world. This included more than $674 million from approximately 2,000 small and diverse businesses in North America, including Puerto Rico.

Our Environmental, Health and Safety team, in partnership with our Office of Supplier Diversity, offers support to small and diverse suppliers with pro-bono services including environmental, health and safety (EHS) audits and sustainability training.

Find out more about our Responsible Supply Chain.

Supporting COVID relief for healthcare system, patients, and underserved communities

Sterilizing worms to eliminate a neglected disease, and coming out of retirement to do it

Tackling tuberculosis, the world’s deadliest infectious disease

We’ve supported ongoing rebuilding and resilience efforts in Puerto Rico—where AbbVie has had a presence for over 50 years—donating $100 million to nonprofit partners Direct Relief and Habitat for Humanity to rebuild the primary health care system and strengthen housing island-wide.

163,000

Hours donated by AbbVie researchers since 2013 to discovering and developing medicines for neglected diseases.

$550M+

Donations to U.S. non-profits from 2013-2020

For the Well-Being of Our Patients

For the Strength
of Our Communities